Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $122,348 | 2 | 99.9% |
| Food and Beverage | $70.56 | 6 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $122,348 | 2 | $0 (2021) |
| Kaleo, Inc. | $23.85 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $22.55 | 2 | $0 (2018) |
| Genentech USA, Inc. | $13.33 | 1 | $0 (2020) |
| SANOFI PASTEUR INC. | $10.83 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $122,348 | 2 | Eli Lilly and Company ($122,348) |
| 2020 | $13.33 | 1 | Genentech USA, Inc. ($13.33) |
| 2019 | $11.45 | 1 | Kaleo, Inc. ($11.45) |
| 2018 | $22.55 | 2 | Merck Sharp & Dohme Corporation ($22.55) |
| 2017 | $23.23 | 2 | Kaleo, Inc. ($12.40) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $28,390.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 07/01/2021 | Eli Lilly and Company | — | — | In-kind items and services | $93,957.79 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 02/24/2020 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Virology & Specialty Care | ||||||
| 06/24/2019 | Kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: ALLERGY | ||||||
| 07/23/2018 | Merck Sharp & Dohme Corporation | ROTATEQ (Biological), GARDASIL9 | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: VACCINE | ||||||
| 03/05/2018 | Merck Sharp & Dohme Corporation | ROTATEQ (Biological), GARDASIL9 | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: VACCINE | ||||||
| 08/09/2017 | SANOFI PASTEUR INC. | MENACTRA (Drug), PENTACEL, ADACEL | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: VACCINES | ||||||
| 02/15/2017 | Kaleo, Inc. | Auvi-Q (Drug) | Food and Beverage | In-kind items and services | $12.40 | General |
| Category: Allergy | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $122,348 | 2 |
About Ernest Leva
Ernest Leva is a Pediatric Emergency Medicine healthcare provider based in Manalapan, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144389537.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ernest Leva has received a total of $122,418 in payments from pharmaceutical and medical device companies, with $122,348 received in 2021. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "" ($122,348).
Practice Information
- Specialty Pediatric Emergency Medicine
- Other Specialties Pediatrics
- Location Manalapan, NJ
- Active Since 12/08/2006
- Last Updated 08/10/2023
- Taxonomy Code 2080P0204X
- Entity Type Individual
- NPI Number 1144389537
Products in Payments
- ROTATEQ (Biological) $22.55
- Xofluza (Drug) $13.33
- Auvi-Q (Drug) $12.40
- AUVI-Q (Drug) $11.45
- MENACTRA (Drug) $10.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.